PR Newswire
Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis
📈
AI Sentiment
Highly Positive
8/10
- Home
- AZN
AZN
AstraZeneca PLC
as of 12-04-2025 3:43pm EST
$89.98
$0.87
-0.96%
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Chart Type:
Time Range:
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 276.3B | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 6.02 | EPS Growth: | 45.02 |
| 52 Week Low/High: | $61.24 - $94.02 | Next Earning Date: | 11-06-2025 |
| Revenue: | $58,127,000,000 | Revenue Growth: | 13.52% |
| Revenue Growth (this year): | 11.33% | Revenue Growth (next year): | 6.08% |
AI-Powered AZN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.83%
74.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Business Wire
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
📈
AI Sentiment
Highly Positive
8/10
Pharma Voice
BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment?
📊
AI Sentiment
Positive
6/10
Business Wire
Snowflake Doubles AWS Marketplace Growth YoY, Eclipses $2 Billion in Sales as New Integrations Accelerate Enterprise Data and AI Adoption
📈
AI Sentiment
Highly Positive
8/10
Zacks
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
📊
AI Sentiment
Positive
7/10
Zacks
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
📊
AI Sentiment
Positive
7/10
Business Wire
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides
📈
AI Sentiment
Highly Positive
8/10
Compare AZN vs Leading Stocks
See how AZN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.